Is the clinical course of HIV-1 changing? Cohort study

BMJ

Volumn 314, Issue 7089, 1997, Pages 1232-

  Sinicco, A ^a   Fora, R ^a   Raiteri, R ^a   Sciandra, M ^a   Bechis, G ^a   Calvo, M M ^a   Gioannini, P ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA 2 MICROGLOBULIN; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; SEX RATIO; TIME;

ADOLESCENT; ADULT; AGE FACTORS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; SEXUAL BEHAVIOR; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0030904351     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.314.7089.1232     Document Type: Article

References (33)

1. Taylor JMG, Kuo JM, Detels R. Is the incubation period of AIDS lengthening? J AIDS 1991; 4: 69–75.
2. Weiss PJ, Brodine SK, Goforth RR, Kennedy CA, Wallace MR, Olson PE, et al. Initial low CD4+ lymphocyte counts in recent human immunodeficiency virus infection and lack of association with identified coinfections. J Infect Dis 1992; 166: 1149–53.
3. Gorham ED, Garland FC, Mayer DL, Goforth RR, Brodine SK, Weiss PJ, et al. CD4 lymphocyte counts within 24 months of human immunodeficiency virus seroconversion. Arch Intern Med 1993; 153: 869–76.
4. O'Brien TR, Hoover DH, Rosemberg PS, Chen B, Detels R, Kingsley LA, et al. Evaluation of secular trends in CD4+ lymphocytes loss among human immunodeficiency virus type 1 (HIV-1)-infected men with known dates of seroconversion. Am J Epidemiol 1995; 142: 636–42.
5. Homberg SD, Conley LJ, Luby SP, Cohn S, Wong LC, Vlahov D. Recent infection with human immunodeficiency virus and possible rapid loss of CD4 T lymphocytes. J AIDS 1995; 9: 291–296.
6. Schwarcz SK, Kellog TA, Kohn RP, Mitchell HK, Lemp GF, Bolan GA. Temporal trends in human immunodeficiency seroprevalence and sexual behavior at the San Francisco municipal sexually transmitted disease clinic. Am J Epidemiol 1995; 142: 314–22.
7. Galai N, Cozzi-Lepri A, Vlahov D, Pezzotti P, Sinicco A, Rezza G. Temporal trends of initial CD4 cell counts following human immunodeficiency virus seroconversion in Italy, 1985-1992. Am J Epidemiol 1996; 143(2):278–83.
8. Centers for Diseases Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987; 36(suppl 1S):3–15S.
9. Cox DR, Oakes D. Analysis of survival data. New York: Chapman Hall, 1984.
10. Statsoft. Statistica 5.0. Tulsa: Statsoft, 1995.
11. SPSS. Statistical package for the social sciences. Version 6.0. Chicago: 1993.
12. Cheng-Mayer C, Seto D, Tateno M, Levy JA. Biologic features of HIV-1 that correlate with virulence in the host. Science 1988; 240: 80–82.
13. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, De Goede REY, Van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66: 1354–60.
14. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4 + T-lymphocyte decline and clinical progression in humanimmunodeficiency virus type 1-infected individuals. J Virol 1993; 67: 1772–1777.
15. Fenyö EM, Morfeldt-Månsson L, Chiodi F, Lind B, Von Gegerfeld A, Albert J, et al. Distinct replicative and cyopathic characteristics of human immunodeficiency virus isolates. J Virol 1992; 66: 4414–4419.
16. Cloyd MW, Moore BE. Spectrum of biologic properties of human immunodeficiency virus isolates. Virology 1990; 174: 103–16.
17. Saag MS, Hahn BH, Gibbons J, Li Y, Parks ES, Parks WP, et al. Extensive variation of human immunodeficiency virus type 1 in vivo. Nature 1988; 334: 440–444.
18. Lee TH, Sheppard HW, Reis M, Dondero D, Osmond D, Osmond D, et al. Circulating HIV-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J AIDS 1994; 7: 381–389.
19. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169: 968–74.
20. St Clair MH, Hartigan PM, Andrews JC, Vavro CL, Simberkoff MS, Hamilton JD and the VA Cooperative Study Group. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J AIDS 1993; 6: 891–897.
21. Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiretroviral drugs. J Clin Invest 1991; 87: 1916–24.
22. Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K, et al. Brief report: primary infection with zidovudine resistant human immunodeficiency virus type 1. N Engl J Med 1993; 328: 1163–1165.
23. Siegrist CA, Yerly S, Kaiser L, Wyler CA, Perrin L. Mother to child transmission of zidovudine resistant HIV-1. Lancet 1994; 344: 1771–1772.
24. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Ayliffe U, Weller IVD, et al. HIV-1 RNA serum load and resistant viral genotypes during early zidovudine therapy. Lancet 1995; 345: 820–824.
25. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science 1989; 246: 1155–1158.
26. Hu DJ, Dondero TJ, Rayfield MA, George JR, Schochetman G, Jaffe HW, et al. Theemerging genetic diversity of HIV. JAMA 1996; 275: 210–216.
27. Lowinson JH, Ruiz P, Millman RB. Comprehensive textbook of substance abuse. 2nd ed. New York: Williams and Wilkins, 1992.
28. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag, 1991.
29. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J AIDS 1990; 3: 144–51.
30. Giorgi JV, Cheng HL, Margolick JB, Bauer KD, Ferbas J, Waxdal M, et al. Quality control in the flow cytometric measurements of T-lymphocyte subsets: the multicenter AIDS cohort study experience. Clin Immunol Immunopathol 1990; 55: 173–86.
31. Adleman LM, Wofsy D. T-cell homeostasis: implications in HIV infection. J AIDS 1993; 6: 144–52.
32. Sinicco A, Fora R, Sciandra M, Lucchini A, Caramello P, Gioannini P. Risk of developing AIDS after primary acute HIV-1 infection. J AIDS 1993; 6: 575–81.
33. Rezza G, Dorrucci M, Pezzotti P, Lazzarin, Angarano, Sinicco A, et al. The seroconversion study on the natural history of HIV infection. In: NicolosiA, ed. HIV epidemiology: models and methods. New York: Raven Press, 1994: 279–91.